Novavax Files For Emergency Use Listing For Its Covid-19 Vaccine Candidate With WHO

US based biotechnology firm Novavax has completed the rolling submission for its Covid-19 vaccine, NVX-CoV237 with the World Health Organization (WHO).

Representational Image | File Image

New Delhi: US based biotechnology firm Novavax has completed the rolling submission for its Covid-19 vaccine, NVX-CoV237 with the World Health Organization (WHO), new agency reported PTI.  

The vaccine has been developed by Novavax in partnership with Serum Institute of India. The company said that their vaccine had already received Emergency Use Authorisation in Indonesia. 

"The company has now completed the submission to World Health Organization (WHO) of all modules required for the regulatory evaluation of NVX-CoV2373, the company's recombinant nanoparticle protein-based Covid-19 vaccine with Matrix-M adjuvant," the company said in a statement. 

The Novavax Inc said that obtaining EUL from WHO is a prerequisite to supply vaccines to various other countries participating in the COVAX Facility. 

Stanley C Erck, Chief Executive Officer and President of Novavax said, "Today's submission reflects our continued focus on accelerating access and equitable distribution as we work to bring our vaccine to people in need around the globe."

The company said that this filing was in addition to the previous filing that the company had along with its partner, Serum Institute of India. The company added that they will make further submissions so that supply can be enabled from other manufacturing sites of Novavax’ global supply chain. 

India’s Bharat Biotech’s vaccine, Covaxin, had also been approved for Emergency Use Listing by the WHO on Wednesday. 

As reported by ANI, the Covaxin had got approval on the recommendation of the Technical Advisory Group (TAG) for Emergency Use Listing (TAG-EUL) which is an independent advisory panel that recommends the WHO regarding Covid-19 vaccines that should be granted approval for emergency use under EUL procedure.